Probiotic Strains Inducing IL-10 for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current probiotic strains are not equally effective in treating inflammatory bowel diseases like Crohn's disease and ulcerative colitis due to differences in survival and persistence in the gastrointestinal tract, strain-specific interactions with the host immune system, and varying capabilities in inducing anti-inflammatory and pro-inflammatory cytokines, necessitating the selection of strains with high anti-inflammatory activity and resistance to gastric and bile salts.
Innovation Solution
A composition comprising live bacteria strains such as Lactobacillus paracasei LMG P-21380, Lactobacillus plantarum LMG P-21021, Bifidobacterium lactis LMG P-21384, and Bifidobacterium breve DSM 16604, which induce high levels of anti-inflammatory cytokine IL-10 and low levels of pro-inflammatory cytokine IL-12, ensuring a favorable IL-10/IL-12 ratio and resistance to gastric and bile salts, is administered orally to treat inflammatory bowel diseases and functional bowel disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If probiotic strains are administered to treat inflammatory bowel diseases, then anti-inflammatory activity is improved, but survival and persistence in the gastrointestinal tract varies among strains
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing specific bacterial strains based on their physiological parameters including resistance to gastric and bile salts, ability to adhere to intestinal epithelium, and capacity to induce anti-inflammatory cytokines. The patent identifies strains with optimal parameter combinations that ensure both survival in the gastrointestinal tract and high anti-inflammatory activity, thereby resolving the contradiction between reliability and adaptability.
2Reliability
If probiotic strains are selected based on strain-specific interactions with the host immune system, then cytokine induction capability is improved, but selection complexity increases
Solution Approach 1:
The patent employs feedback mechanisms by establishing in vitro assays that measure cytokine induction capability (IL-10, IL-12, TNF-α) of probiotic strains. These assays provide quantitative feedback on strain performance, enabling systematic selection of strains with desired immunomodulatory profiles. The feedback from these standardized tests guides the selection process, reducing complexity while ensuring reliable cytokine induction capability.
3Reliability
If probiotic strains with high anti-inflammatory activity are selected, then therapeutic effectiveness is improved, but resistance to gastric and bile salts must be ensured
Solution Approach 1:
The patent applies preliminary action by pre-screening probiotic strains for resistance to gastric acid and bile salts before evaluating their anti-inflammatory activity. This preliminary selection ensures that only strains capable of surviving the harsh gastrointestinal environment are further tested for therapeutic effectiveness. By performing this resistance assessment in advance, the patent eliminates strains that would be destroyed by gastric and bile salts, ensuring that selected strains possess both survival capability and high anti-inflammatory activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selected bacteria strains effectively induce IL-10 production, maintain a high IL-10/IL-12 ratio, and persist in the gastrointestinal tract, providing therapeutic benefits for inflammatory bowel diseases and functional bowel disorders while being safe and resistant to antibiotic resistance.
Implementation Method 1
The bacteria strains according to the present invention are useful in that they are capable of inducing the production of interleukin-10 (IL-10) and/or modulating the levels of cytokines in the host
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory 11-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient.